Holen Sie sich die Stockscreener-App
3.95
4.13%
-0.17
Handel nachbörslich:
3.97
0.02
+0.51%
Schlusskurs vom Vortag:
$4.12
Offen:
$4.18
24-Stunden-Volumen:
88,043
Relative Volume:
0.67
Marktkapitalisierung:
$12.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.21M
KGV:
-0.1212
EPS:
-32.6
Netto-Cashflow:
$-16.86M
1W Leistung:
-5.50%
1M Leistung:
-12.61%
6M Leistung:
-43.57%
1J Leistung:
-75.44%
1-Tages-Spanne:
$3.90
$4.18
1-Wochen-Bereich:
$3.90
$4.365
52-Wochen-Spanne:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Firmenname
Cingulate Inc
Sektor
Branche
Telefon
(913) 942-2300
Adresse
1901 W. 47TH PLACE, KANSAS CITY
Vergleichen Sie CING mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
3.95 | 12.88M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2023-12-22 | Herabstufung | Laidlaw | Buy → Hold |
Cingulate Inc Aktie (CING) Neueste Nachrichten
Cingulate (NASDAQ:CING) Trading Down 2.1% – Here’s Why - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright - MSN
Cingulate CEO cleared of charges, retains board confidence - Investing.com India
Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia
Q4 Earnings Forecast for Cingulate Issued By HC Wainwright - Defense World
Cingulate (NASDAQ:CING) Price Target Raised to $20.00 - Defense World
Cingulate Inc. adjusts executive compensation - MSN
Brokers Issue Forecasts for Cingulate FY2025 Earnings - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Public company CEO concludes case alleging aggravated domestic battery - The Business Journals
Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com Australia
Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World
Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada
Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World
Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World
Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN
CINGWCingulate Inc. Warrants Latest Stock News & Market Updates - StockTitan
Cingulate Inc Completes Key FDA Study for ADHD Drug - TipRanks
Final Study Completed for Cingulate’s Lead Asset CTx-1301 - GlobeNewswire
Cingulate Completes Final FDA Study for Once-Daily ADHD Drug CTx-1301 with Zero Safety Issues - StockTitan
Cingulate Inc. Enters into Note Purchase Agreement with Streeterville Capital, LLC - Defense World
Cingulate secures capital ahead of 2025 plans to submit drug for FDA approval - The Business Journals
Cingulate Inc Secures $5M Financing for Strategic Growth - Yahoo Finance
Cingulate Inc. announced that it has received $5 million in funding - Marketscreener.com
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - GlobeNewswire
Cingulate Secures $5M Financing Deal to Advance CTx-1301 Drug Development Through 2025 - StockTitan
Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World
Cingulate Inc (CING) Quarterly 10-Q Report - Quartz
CINGCingulate Inc. Latest Stock News & Market Updates - StockTitan
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year - TipRanks
Cingulate Reports Third Quarter 2024 Financial - GlobeNewswire
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - StockTitan
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire
Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa
SEC Form 424B3 filed by Cingulate Inc. - Quantisnow
Cingulate secures funding to extend operations into Q2 2025 - Investing.com India
Cingulate Inc Files for 1.5M Share Offering by Selling Stockholders - Investing.com Canada
Finanzdaten der Cingulate Inc-Aktie (CING)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):